39 articles - From Friday Sep 09 2022 to Friday Sep 16 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Rheumatology (Oxford) |
Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis. Guselkumab demonstrates better skin efficacy than most other targeted PsA therapies, including upadacitinib. For vdH-S, both guselkumab doses are comparable to most treatments, with both doses ranking higher than most, including upadacitinib and risankizumab. Both guselkumab doses demonstrate comparable ACR responses to most other agents, including upadacitinib and risankizumab, and rank favorably in the network for SAEs. |
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries. After failing the first JAKi, cycling JAKi and switching to a bDMARD appear to have similar effectiveness. Caution is advised if an AE was the reason to stop the first JAKi. |
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study. Ninety-six per cent of patients withdrawn to placebo recaptured at least ASDAS LDA and 71% recaptured ASDAS ID with IXE retreatment at week 104. This may provide support to patients who may require a brief interruption in therapy. |
| Arthritis Care Res (Hoboken) |
Association of Area-Level Heat and Social Vulnerability with Recurrent Hospitalizations among Individuals with Rheumatic Conditions. Individuals with rheumatic conditions living in areas with high vs low social and heat vulnerability had significantly greater odds of recurrent hospitalizations. Studies are needed to determine modifiable factors to mitigate risks. |
Association of Sleep Deprivation and the Risk of Developing Systemic Lupus Erythematosus among Women. Chronic low sleep duration was associated with higher SLE risk, with stronger effects among those with bodily pain and depression, highlighting the potential role of adequate sleep in disease prevention. |
Association of systemic sclerosis with incident clinically evident heart failure. SSc is associated with a markedly higher risk of clinically evident HF, and not asymptomatic ventricular dysfunction alone. These findings provide real-world evidence suggesting the use of appropriate screening strategies to detect these lethal complications early in SSc. |
Cost effectiveness of telehealth-delivered exercise and dietary weight loss programs for knee osteoarthritis within a 12-month randomised trial. Telehealth-delivered programs targeting exercise with dietary intervention for people with knee OA who have overweight/obesity are likely to be cost-effective, particularly if potential long-term gains from weight loss and work productivity are realised. |
Incident gout and risk of first-time acute coronary syndrome: a prospective, population-based, cohort study in Sweden. Patients with incident gout have a 44% increased risk of first-time ACS, higher in women than in men. This risk is largely explained by the underlying comorbidities, but there is still a modestly increased risk that may be due to gout-related factors. |
| Arthritis Res Ther |
Autologous Protein Solution processing alters lymphoid and myeloid cell populations and modulates gene expression dependent on cell type. Gene expression profiling revealed that APS processing results in differential gene expression changes dependent on immune cell type, with the most significantly differentially regulated genes occurring in the monocytes. Our results demonstrate that the mechanical processing of blood, whose main purpose is enrichment and separation, can alter its protein and cellular composition, as well as cellular phenotypes in the final product. |
Defining the relationship between pain intensity and disease activity in patients with rheumatoid arthritis: a secondary analysis of six studies. These findings show pain intensity is an integral part of disease activity, though it is not measured directly in DAS28-ESR. Reducing disease activity is crucial for reducing pain intensity in RA. |
Subclinical systolic and diastolic myocardial dysfunction in polyphasic polymyositis/dermatomyositis: a 2-year longitudinal study. Significant subclinical cardiac dysfunction could be detected in IIM patients with polyphasic disease course 2 years after diagnosis, which identifies them as a high-risk population. TDI is a useful method to detect echocardiographic abnormalities in IIM complementing conventional echocardiography and can recognize the high cardiac risk. |
Synoviocytes and skin fibroblasts show opposite effects on IL-23 production and IL-23 receptor expression during cell interactions with immune cells. Interactions between immune and stromal cells are crucial in cytokine production and their receptor expression. The origin of stromal cells had a major influence on the production of IL-23 and its receptor expression. Such differences may explain part of the heterogeneity in treatment response. |
| Arthritis Rheumatol |
A Randomized Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT): Primary Efficacy and Safety Findings. MTX co-therapy markedly increased pegloticase response rate over PBO (71.0% vs 38.5%) during Month-6 with no new safety signals. These findings verify higher treatment response rate, lower IR incidence, and lower immunogenicity when pegloticase is co-administered with MTX. |
Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study. These general population data suggest that individuals with gout, especially women, have higher risks of both SARS-CoV-2 infection and severe sequelae, even with vaccinations. |
Increased Expression of LMCD1 in Scleroderma-Associated Interstitial Lung Disease is Critical for Profibrotic Characteristics of Lung Myofibroblasts. Our study identifies LMCD1 as a profibrotic molecule contributing to the activation of myofibroblasts and the persistent fibroproliferation observed in SSc-ILD. Thus, LMCD1 may be a potential novel therapeutic target for patients with SSc-ILD. |
Inhibitor of nuclear factor kappa-B kinase epsilon contributes to neuropsychiatric manifestations in lupus-prone mice through microglial activation. These findings suggest that IKBKE plays a vital role in the pathogenesis of NPSLE via microglial activation, and it could serve as a therapeutic target for NPSLE. |
| Rheumatology (Oxford) |
Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis. CMR may distinguish between reversible inflammatory/fibrotic and irreversible fibrotic lesions in SSc patients with active myocarditis, confirming the unique nature of primary cardiac involvement in SSc. Whether, and how, CMR should be used to monitor treatment effects in SSc-associated myocarditis warrants further study. |
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behcet's disease versus the general population. In this large population-based cohort study, BD patients compared with the general population have a 10.73-fold risk of blindness in 10-years and also a substantially higher risk of diverse ocular comorbidities that pose potential threats to vision. |
SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis. Monitoring urinary BAFF-bioactivity may be valuable in diagnosing LN. Furthermore, stratification based on serum BAFF and IFN-I bioactivities may allow the identification of appropriate patients for biologics targeting BAFF and IFN-I. |
Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis. This analysis identified factors associated with successful cessation of biologics for remission in JIA as absence of uveitis, prior treatment with tocilizumab and starting biologics earlier in the disease course. Further research is needed to guide clinical recommendations. |
Survival and Prognostic factors from a multicentre large cohort of unselected Italian Systemic Sclerosis patients. In the last decade, SSc patients have reached similar mortality of that expected in the Italian general population. Male gender, diffuse cutaneous involvement, comorbidities, and PAH with or without ILD represent the main poor prognostic factors. |
The influence of age on the prevalence of inflammatory and structural MRI lesions in the SIJ of patients with and without axSpA. The proportion of patients with MRI lesions was high in both, axSpA and non-SpA patients. However, the prevalence of BME and erosions was significantly more frequent in patients with axSpA, was independent of age and also allowed for discrimination. FL occurred more frequently only in older age groups and were less reliable for discrimination vs non-SpA patients. |
Treating spondyloarthritis early: does it matter? Results from a systematic literature review. Evidence towards better outcomes in early axSpA is very limited and restricted to nr-axSpA and <5 years symptom duration. When early axSpA is defined based on disease duration or radiographic damage, no differences in response to treatment are found. |
Work participation is unaffected in Belgian spondyloarthritis patients: data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT. Evidence from this academic cohort study does not support a work participation gap between SpA patients and the general population, but confirms the role of physical function, overall HRQoL, and education or job type as risk factors for adverse work outcomes. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Arthritis Care Res (Hoboken) |
Socioeconomic Status and Medication Use in Rheumatoid Arthritis: A Scoping Review. There is some evidence that SES affects use of medications in patients with RA, however multiple definitions of SES have been utilised, making comparisons between studies difficult. Prospective studies with consistently defined SES will be needed to determine whether differences in medication use accounts for the poorer outcomes experienced by lower SES patients. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Ann Rheum Dis |
| Rheumatology (Oxford) |